Phase 3Completed
Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)
A Randomized, Double-Blind Study of the Efficacy and Safety of Alirocumab Added on to Atorvastatin Versus Ezetimibe Added on to Atorvastatin Versus Atorvastatin Dose Increase Versus Switch to Rosuvastatin in Patients Who Are Not Controlled on Atorvastatin
- Sponsor
- Regeneron Pharmaceuticals (Industry)
- Enrollment
- 355 enrolled
- Conditions
- Hypercholesterolemia
- Interventions
- Alirocumab; Atorvastatin; Ezetimibe; Rosuvastatin; Placebo
- Ages
- adults, older adults
- Registry
- NCT01730040
Full record on ClinicalTrials.gov
From the registry
This is a randomized, double-blind, active-comparator, parallel-group study in patients at high cardiovascular risk with nonfamilial hypercholesterolemia or heterozygous familial hypercholesterolemia (heFH).
Primary outcomes
- Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis
History
Results first posted
Last registry update
Study completion
Primary completion
Registered
Started